Private Equity Analyst Interview Questions

I start with the sources and uses table: uses are the purchase price plus fees, sources are the debt tranches, the sponsor equity cheque, and any rollover equity from management. I set the purchase price off an entry EV/EBITDA multiple, typically anchored to comparable transactions. On the debt side I size each tranche off a leverage multiple, say 5.5x EBITDA total debt split across a term loan and possibly a second lien, then build the debt schedule with mandatory amortisation and a cash sweep. I project the income statement and free cash flow, working down from revenue growth and margin assumptions to unlevered free cash flow, then layer in interest expense, which is circular with the cash balance, so I use a toggle to switch off circularity while auditing the model. At exit I apply an exit multiple, usually flat or slightly below entry to be conservative, back out net debt, and calculate the equity proceeds. From there I derive the IRR and the money multiple across the hold period. I always sensitise entry multiple, exit multiple, leverage, and EBITDA growth against each other.

I start with why this business would be attractive to own with leverage: stable, recurring cash flows, high free cash flow conversion, and a defensible market position, since debt service does not forgive a bad quarter. I look at revenue quality first: contracted or repeat revenue is worth more than one-off project work. Then I assess the margin structure and whether there is a credible path to expand it, through pricing, procurement, or overhead rationalisation. I build a base case around organic growth and identify two or three specific value creation levers with rough sizing, not just "operational improvement" as a category. I also stress-test the downside: what happens to the covenant headroom if EBITDA falls 15 percent in year two. Finally I look at the exit landscape: is there a realistic pool of strategic or financial buyers in three to five years, or are we relying on an IPO window that may not exist. A thesis without a credible exit path is not a thesis.

Due diligence runs in parallel workstreams. Commercial diligence, usually with a consulting firm, tests the market size, competitive position, and customer concentration, and I read the customer interview transcripts closely rather than just the summary slide. Financial diligence, typically with an accounting firm, normalises EBITDA for one-off items and tests working capital and quality of earnings: I pay particular attention to the gap between reported EBITDA and cash EBITDA, since that gap is where inflated valuations hide. Legal diligence covers contracts, litigation, and change of control provisions in customer or supplier agreements, which can derail a deal if a top customer can walk on acquisition. I also run management diligence myself: does the leadership team have the bench strength to execute the plan, or does the thesis depend on one person. My job as the analyst is to synthesise findings across workstreams into a single view of the risks that actually move the valuation, not to produce a hundred-page report nobody reads.

I worked on the acquisition of a specialty distribution business with revenue of around 180 million euros and EBITDA margins of 14 percent. Our thesis was that the company had underinvested in its sales force and pricing discipline under the previous family ownership, and that a modest investment in both could expand margins by 250 to 300 basis points over three years without needing to change the underlying business model. I built the LBO model at a 7.5x entry multiple with 5x leverage, and my base case showed a 2.4x money multiple and roughly 22 percent IRR over a five-year hold, assuming exit at a flat multiple. During diligence I found that customer concentration was higher than the CIM suggested, with the top five customers at 38 percent of revenue rather than the 28 percent stated, which we flagged and used to negotiate a two-turn reduction in the entry multiple. The deal closed at 6.9x, and the revised base case IRR moved to roughly 26 percent.

On a consumer products deal, a managing director wanted to underwrite 8 percent annual organic growth based on the last two years of performance, which had been boosted by a temporary category tailwind during a period of elevated consumer spending. I pulled category-level data going back ten years and showed that growth had averaged closer to 3 percent outside the anomalous period, and that underwriting 8 percent would require the tailwind to persist indefinitely, which nothing in the data supported. Rather than simply stating I disagreed, I brought the analysis and proposed a base case at 4 percent with an upside case at 7 percent so the committee could see both scenarios and the assumptions driving each. The MD pushed back initially, but agreed to present both cases to the investment committee. The committee ultimately approved the deal on the conservative case with an earnout structure tied to the upside scenario, which protected the fund if growth reverted to trend. Being right on the data mattered less than presenting it in a way that gave the decision-maker options rather than a confrontation.

At a portfolio company in the industrials sector, the CFO was reporting monthly numbers that consistently missed budget by small margins that management attributed to timing. I sat with the finance team for two days and found the gap was actually a systematic overestimation of gross margin in the forecasting model, not timing. Rather than escalating this immediately as a management competence issue, I worked with the CFO directly to rebuild the forecasting model using actual historical conversion rates by product line, and I framed it as a tooling problem rather than a performance problem, since the relationship with management needed to survive the fix. The next quarter's forecast came within 2 percent of actuals for the first time in a year. The board took this as a signal that the CFO could be developed rather than replaced, which mattered because a CFO transition mid-hold would have been disruptive to a refinancing we had planned for later that year.

During an auction process, I had roughly ten days to build the LBO model, complete a first pass of commercial diligence, and draft the investment committee memo, while also supporting two other live deals at earlier stages. I prioritised by asking what specifically had to be true for the deal to clear the return hurdle, and focused my first two days entirely on that: the leverage capacity and the realistic exit multiple, since if those did not work the rest of the analysis was moot. Once the model confirmed the deal could clear our hurdle at a sensible entry price, I sequenced the remaining work: diligence questions that could kill the deal came before diligence questions that only refined the valuation. I communicated daily with the deal lead on what was done, in progress, and at risk, rather than going quiet and surfacing problems only at the deadline. We submitted the IC memo on time with two open items clearly flagged rather than either missing the deadline or submitting something that looked complete but was not. Sustained pressure is manageable when the sequencing is right; it becomes unmanageable when everything is treated as equally urgent.

A DCF answers the question of what a business is intrinsically worth based on its own cash flow generation, independent of how it is financed: you discount unlevered free cash flows at the weighted average cost of capital. An LBO model answers a different question entirely: given a target return, usually 20 to 25 percent IRR for a typical buyout fund, what is the maximum price I can pay for this business using a realistic amount of leverage. The LBO is a reverse-engineered pricing tool anchored to a required return, not a valuation of intrinsic worth. The two are connected: I often run a DCF first to understand standalone value, then use the LBO to check whether that value supports an acceptable sponsor return given achievable leverage and exit assumptions. If the DCF value is well above what the LBO can support at the target return, either the deal does not work at that price or the value creation plan needs to close the gap. Conflating the two is a common mistake: an LBO output is not a fair value, it is the maximum price consistent with hitting a hurdle.

IRR in an LBO is driven by three levers: EBITDA growth, multiple expansion or contraction, and deleveraging, plus the effect of leverage itself magnifying equity returns. EBITDA growth comes from revenue growth and margin expansion, and is usually the largest driver over a typical five-year hold if the operating plan executes. Multiple expansion, buying at a low multiple and exiting at a higher one, can be a significant contributor but is the riskiest to underwrite since it depends on market conditions at exit that are outside the sponsor's control; I generally model exit at or below entry multiple to avoid relying on it. Deleveraging, paying down debt with free cash flow over the hold period, converts debt into equity value and is a mechanical, low-risk contributor to returns, which is why highly cash-generative businesses are attractive LBO targets even without much growth. Leverage itself amplifies whatever equity return the underlying enterprise value growth produces, but it cuts both ways: the same mechanism that produces a 3x money multiple on a successful deal can produce a total loss if EBITDA falls and the business cannot service its debt. A well-underwritten deal should generate an acceptable return from EBITDA growth and deleveraging alone, treating multiple expansion as upside rather than a requirement.

I separate value creation into three buckets. Operational improvement covers pricing discipline, procurement savings, SG&A rationalisation, and working capital efficiency, and it is the lever most within the sponsor and management team's control, so I underwrite it conservatively but expect it to be delivered. Growth initiatives, such as entering adjacent geographies, cross-selling across a buy-and-build platform, or launching new products, carry more execution risk and I typically underwrite them at a discount to management's own projections, maybe 60 to 70 percent of the plan. Financial engineering, meaning deleveraging and refinancing to a cheaper cost of debt as the business de-risks, is largely mechanical once the operating plan is on track. For a buy-and-build strategy specifically, I track a separate metric: whether add-on acquisitions are being bought at a lower multiple than the platform trades at, since multiple arbitrage on add-ons is often the single largest source of value creation in that strategy, more than organic growth in either the platform or the targets.